Search
Migraine Clinical Trials in Pittsburgh, PA
A listing of 3 Migraine clinical trials in Pittsburgh, PA actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 3 of 3
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Migraine
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The city of Pittsburgh, Pennsylvania, currently has 3 active clinical trials seeking participants for Migraine research studies.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Kids and Teens Migraine Clinical Study
Recruiting
We are looking for adolescents who experience migraines to take part in a clinical trial. No health insurance is required. The study medicine and any trial-related procedures will be provided.
Conditions:
Migraine
Migraine Disorders
Migraine Headache
Chronic Migraine
Migraine Without Aura
Featured Trial
Migraine Clinical Trial
Recruiting
Over 39 million people in the US suffer from migraines. You are not alone! If you are struggling with migraines, consider joining a clinical trial to help us study potential new treatment options. All eligible participants will receive no-cost study-related care and study medication. You may also receive compensation for your study-related time and/or travel.
Conditions:
Migraine
Migraine Disorders
Migraine Headache
Chronic Migraine
Migraine Without Aura
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
06/11/2025
Locations: Preferred Primary Care Physicians, Inc, Pittsburgh, Pennsylvania
Conditions: Migraine
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Recruiting
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
05/22/2025
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania +1 locations
Conditions: Episodic Migraine
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
05/20/2025
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Chronic Migraine
1 - 3 of 3